<DOC>
	<DOCNO>NCT01575808</DOCNO>
	<brief_summary>The utility GP1101 evaluate relative surgical bypass treatment Femoral/Popliteal Arterial Symptomatic Peripheral Arterial Disease . Efficacy measure comparison Surgical Bypass Efficacy Goal , Invasiveness measure comparison Surgical Bypass data derive retrospective study .</brief_summary>
	<brief_title>Multi-center Study Stent Graft System Peripheral Artery</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Rutherford 25 category Subject read , understood sign write informed consent review approved Institutional Review Board ( IRB ) . At least 20 year age . Anklebrachial index ( ABI ) study limb noninvasive low extremity arterial study within 30 day prior study procedure time study procedure less equal 0.9 , toebrachial index ( TBI ) less equal 0.5 . Male , infertile female , female childbearing potential practicing acceptable method birth control negative pregnancy test within 7 day prior study procedure . Projected life expectancy great 2 year . The ability comply study protocol , followup requirement require test . Surgical bypass candidate Qualifying lesion angiography Untreated flowlimiting aortoiliac disease . Any previous stenting surgery target vessel ( i.e . femoropopliteal artery ) . Vascular access/catheterization target contralateral limb within 30 day study enrollment . Planned surgery intervention within 30 day study procedure . Femoral artery popliteal artery aneurysm &gt; 1.5 X healthy adjacent vessel diameter . Nonatherosclerotic disease result stenosis and/or occlusion ( e.g. , embolism , Buerger 's disease , vasculitis ) . Severe medical comorbidities ( untreated CAD/CHF ( Congestive Heart Failure ) , severe COPD ( Chronic Obstructive Pulmonary Disease ) , severe dementia , NYHA ( New York Heart Association ) 3/4 , severe hypertension , etc . ) Any medical condition would preclude postprocedural ambulation completion study followup . Rutherford 5 patient active infection . Serum creatinine &gt; 2.5 mg/dL within 30 day prior study procedure.3 Rutherford 6 category study nonstudy limb major tissue loss extend proximal phalanx level . Rutherford 5 characteristic nonstudy limb . Major distal amputation ( transmetatarsal ) study nonstudy limb . Active infection could adversely impact patient outcome study , patient septicemia bacteremia . Any previously know coagulation disorder , include hypercoagulability . Morbid obesity operative scarring precludes percutaneous approach Contraindication anticoagulation antiplatelet Known allergy stent/stentgraft component , include heparin sensitivity , allergy , previous incidence heparininduced thrombocytopenia ( HIT ) type II . Current peritoneal hemodialysis Participation another clinical trial ( except F/P device clinical trial ) 3 month prior study enrollment . Enrollment F/P device clinical trial within last 12 month . Interventional surgical treatment artery distal target vessel study within past 12 month . Any factor identify Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Symptomatic PAD</keyword>
	<keyword>stenosed occlude lesion</keyword>
	<keyword>total least 10 cm length</keyword>
	<keyword>Rutherford score 2-5</keyword>
</DOC>